Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.

Gaurav SyalGil Y MelmedChristopher V AlmarioBrennan M R Spiegel

Published in: Digestive diseases and sciences (2022)

Azathioprine withdrawal is the most effective and least costly de-escalation strategy in CD patients in remission on combination therapy if AZA re-introduction is performed upon CD relapse.

Keyphrases

combination therapy
end stage renal disease
ulcerative colitis
ejection fraction
chronic kidney disease
newly diagnosed
disease activity
prognostic factors
peritoneal dialysis
randomized controlled trial
systemic lupus erythematosus
open label
rheumatoid arthritis
nk cells
patient reported outcomes